Terfenadine, a second histamine H1 receptor antagonist has previously been reported for its apoptosis-inducing properties against a variety of cancer cells [90–92], including human melanoma cells [93, 94] and more recently prostate cancer cells [95]. Here, HRH1 is linked to melanoma.